Filing Flows › Kewaunee Scientific (KEQU) › Takeover & LBO
Is Kewaunee Scientific (KEQU) a takeover target?
A leveraged buyout does not work for Kewaunee Scientific on its latest figures: the figures a buyout model needs (revenue, EBITDA, the share count and the price) are not all on file. Latest signal (2026-11-02): Kewaunee Scientific Announces Agreement to Acquire Nycom, Inc..
Why a leveraged buyout does not fit
The buyout model needs Kewaunee Scientific's revenue, EBITDA, share count and share price; not all of them are on file, so it gives no buyout price.
What a takeover could cost
Takeovers in its sector paid a median premium of 40% over the share price before the deal (the middle half 14.7% to 60.2%), according to the 20 merger proxies and tender-offer responses on EDGAR that state a premium.
Rumors and deal signals
- 2026-11-02 · 8-K deal · Kewaunee Scientific Announces Agreement to Acquire Nycom, Inc.
Kewaunee Scientific's latest quarter
Kewaunee Scientific, Q1 FY27: revenue $66.3M (-7% year over year), operating margin 4.8%, net earnings $1.7M, operating cash flow $2.0M. The chart follows the revenue to costs, profit and cash.
Questions
Is Kewaunee Scientific being acquired?
The latest signal on file is from 2026-11-02: Kewaunee Scientific Announces Agreement to Acquire Nycom, Inc.. A headline is not a deal; Filing Flows lists the news, 8-K filings and 13D filings about a sale.
Could private equity buy Kewaunee Scientific?
A leveraged buyout does not work for Kewaunee Scientific on its latest figures: the figures a buyout model needs (revenue, EBITDA, the share count and the price) are not all on file. The model gives no buyout price until they are.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.